Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 1356 and Glyburide
NCT02183428Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of glyburide in plasma from time zero to infinity up to 48 hours, Maximum measured concentration of glyburide in plasma up to 48 hours and 2 more. Started May 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183428.